New hope for Tough-to-Treat blood cancer: experimental injection takes on standard therapy

NCT ID NCT07452198

Recruiting now Disease control Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new injection called GR1803 works better than the current standard treatment for multiple myeloma that has returned or stopped responding to previous therapies. It will involve about 358 adults whose cancer has progressed after 1-3 prior treatments that included specific medications. Researchers will randomly assign participants to receive either the new injection or the standard three-drug combination to compare how long the cancer stays under control.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA